Online Medicine

Product Warranty

Payment Methods

payment-logo

About the Product

Full Description

\n
\n
\n
\n
\n
Each film coated tablet contains Tofacitinib Citrate INN 8 mg equivalent to Tofacitinib 5 mg.
\n
\n
\n
\n
\n
\n
\n
\n \n
\n
\n
Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis and psoriatic arthritis. Tofacitinib inhibits JAK dependent cytokine signaling. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane. JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Tofacitinib prevents the phosphorylation and activation of STATs thus downregulates the production of cytokines by inhibiting JAK.
\n
\n
\n
\n \n
Rheumatoid Arthritis: Arthanib/Arthanib XR Tablet is indicated for the treatment of adult patients with moderate to severe rheumatoid arthritis. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs). Psoriatic Arthritis: Arthanib/Arthanib XR Tablet is indicated for the treatment of adult patients with active psoriatic arthritis. It may be used in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs). Ulcerative Colitis: Arthanib/Arthanib XR Tablet is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis
\n
\n
\n
\n \n
Rheumatoid Arthritis & Psoriatic Arthritis patients: The recommended dose is Arthanib 5 mg twice daily or Arthanib XR 11 mg once daily with or without food. Ulcerative colitis patients: The recommended dose is Arthanib10 mg twice daily for at least 8 weeks; then Arthanib 5 or 10 mg twice daily
\n
\n
\n
\n \n
Contraindicated in patients with known hypersensitivity to Tofacitinib or any other component of this product. It is contraindicated in severe hepatic impaired patients.
\n
\n
\n
\n \n
Avoid use of Tofacitinib during an active serious infection, including localized infections. Use with caution in patients that may be at increased risk of Gastrointestinal Perforations. Avoid use of Tofacitinib concurrently with Immunizations - Live vaccines. Storage: Store below 300 C at dry place, protect from light and moisture. Keep out of the reach of children.
\n
\n
\n \n
\n
The most commonly reported adverse reactions are upper respiratory tract infections, headache, diarrhea and nasopharyngitis.
\n
\n
\n
\n \n
Tofacitinib exposure is increased when coadministered with potent inhibitors of cytochrome P450 (CYP) 3A4 (e.g., ketoconazole) & medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole). Tofacitinib exposure is decreased when coadministered with potent CYP3A4 inducers (e.g., rifampin). There is a risk of added immunosuppression when Tofacitinib is coadministered with potent immunosuppressive drugs (e.g., azathioprine, tacrolimus, cyclosporine). Use of Tofacitinib in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
\n
\n
\n
\n \n
Use in pregnancy: Pregnancy Category C. There are no adequate and wellcontrolled studies in pregnant women. Tofacitinib should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Use in lactation: It is not known whether Tofacitinib is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug for the mother. Pediatric use: The safety and effectiveness of Tofacitinib in pediatric patients have not been established. Hepatic impairment: No dose adjustment is required in patients with mild hepatic impairment. For moderate hepatic impairment patients recommended dose is Tofacitinib 5 mg once daily. Use of Tofacitinib in patients with severe hepatic impairment is not recommended. Renal impairment: No dose adjustment is required in patients with mild renal impairment. For patients with moderate and severe renal impairment recommended dose is Tofacitinib 5 mg once daily.
\n
\n
\n
\n \n
Each box contains 10\'s tablets in alu-alu blister pack.
\n
\n
\n
\n
\n
\n
\n

Reviews:


No Review



Cart

0 Items

0
Cart 0 Item
close
close

Your purchase will delivered in 1 shipment

Express delivery
Empty

Your shopping bag is empty. Start shopping now.